5 December 2024
The Quest to Turn Human Waste Into Medicine
After success in early stage trials, MaaT Pharma is on the verge of becoming the first company to have an approved microbiome-related product for cancer care.
All
3 December 2024
Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target
Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to...
26 November 2024
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
19 November 2024
Cmbio: A New Brand Unifying Leaders in Microbiome and Metabolomics Science
Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba's...
13 November 2024
Enterome to host webinar on new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of lead programme, EO2463
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through...
6 November 2024
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced that clinical data from the...
4 October 2024
La Vie closes €25 million fundraising round
Watch the replay of Good Morning Business, on BFM Business with interviews with Nicolas Schweitzer, co-founder of La Vie ™, a company in our HFL portfolio, interviewed by...
3 October 2024
Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.
Citryll, a clinical-stage biotech company developing first-inclass therapeutics to treat immune-mediated inflammatory diseases, today announces a groundbreaking collaboration...
24 September 2024
Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications
Sequentia Biotech, a #deeptech and leading bioinformatics company focused on the analysis and application of omics data, announces a €10million Series A, led by Seventure...